Overexpression of c-Maf contributes to T-cell lymphoma in both mice and human

Cancer Research

Volumn 66, Issue 2, 2006, Pages 812-819

  Morito, Naoki ^a   Yoh, Keigyou ^a   Fujioka, Yuki ^a   Nakano, Takako ^a   Shimohata, Homare ^a   Hashimoto, Yuko ^a   Yamada, Akiko ^a   Maeda, Atsuko ^a   Matsuno, Fumihiko ^b   Hata, Hiroyuki ^b   Suzuki, Atsushi ^c   Imagawa, Shigehiko ^a   Mitsuya, Hiroaki ^b   Esumi, Hiroyasu ^c   Koyama, Akio ^a   Yamamoto, Masayuki ^a   Mori, Naoyoshi ^d   Takahashi, Satoru ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

^c NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^d NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA7 INTEGRIN; CYCLIN D2; GENE PRODUCT; PROTEIN ARK5; TRANSCRIPTION FACTOR C MAF; UNCLASSIFIED DRUG;

ANGIOIMMUNOBLASTIC LYMPHADENOPATHY; ANIMAL CELL; ARTICLE; C MAF GENE; CELL COMPARTMENTALIZATION; GENE OVEREXPRESSION; GENE TARGETING; GENE TRANSLOCATION; HUMAN; HUMAN CELL; MALIGNANT TRANSFORMATION; MOUSE; MULTIPLE MYELOMA; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; T CELL LYMPHOMA;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; CYCLINS; GENE EXPRESSION PROFILING; HUMANS; INTEGRIN BETA CHAINS; LYMPHOMA, T-CELL; MICE; PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-MAF; REPRESSOR PROTEINS; UP-REGULATION;

EID: 31544476523     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-2154     Document Type: Article

References (34)

1. Nishizawa M, Kataoka K, Goto N, Fujiwara KT, Kawai S. v-maf, a viral oncogene that encodes a "leucine zipper" motif. Proc Natl Acad Sci U S A 1989;86:7711-5.
2. Kataoka K, Noda M, Nishizawa M. Maf nuclear oncoprotein recognizes sequences related to an AP-1 site and forms heterodimers with both Fos and Jun. Mol Cell Biol 1994;14:700-12.
3. Swaroop A, Xu J, Pawar H, Jackson A, Skolnick C, Agarwal N. A conserved retina-specific gene encodes a basic motif/leucine zipper domain. Proc Natl Acad Sci USA 1992;89:266-70.
4. Ogino H, Yasuda K. Induction of lens differentiation by activation of a bZIP transcription factor, L-Maf. Science 1998;280:115-8.
5. Kajihara M, Kawauchi S, Kobayashi M, Ogino H, Takahashi S, Yasuda K. Isolation, characterization, and expression analysis of zebrafish large Mafs. J Biochem (Tokyo) 2001;129:139-46.
6. Ho IC, Hodge MR, Rooney JW, Glimcher LH. The proto-oncogene c-maf is responsible for tissue-specific expression of interleukin-4. Cell 1996;85:973-83.
7. Kawauchi S, Takahashi S, Nakajima O, et al. Regulation of lens fiber cell differentiation by transcription factor c-Maf. J Biol Chem 1999;274:19254-60.
8. Kim JI, Li T, Ho IC, Grusby MJ, Glimcher LH. Requirement for the c-Maf transcription factor in crystallin gene regulation and lens development. Proc Natl Acad Sci U S A 1999;96:3781-5.
9. Ring BZ, Cordes SP, Overbeek PA, Barsh GS. Regulation of mouse lens fiber cell development and differentiation by the Maf gene. Development 2000;127:307-17.
10. Chesi M, Bergsagel PL, Shonukan OO, et al. Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma. Blood 1998;91:4457-63.
11. Kuehl WM, Bergsagel PL. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer 2002;2:175-87.
12. Seidl S, Kaufmann H, Drach J. New insights into the pathophysiology of multiple myeloma. Lancet Oncol 2003;4:557-64.
13. Hurt EM, Wiestner A, Rosenwald A, et al. Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell 2004;5:191-9.
14. Kienast J, Berdel WE. c-maf in multiple myeloma: an oncogene enhancing tumor-stroma interactions. Cancer Cell 2004;5:109-10.
15. Zhumabekov T, Corbella P, Tolaini M, Kioussis D. Improved version of a human CD2 minigene based vector for T cell-specific expression in transgenic mice. J Immunol Methods 1995;185:133-40.
16. Rabbitts TH, Forster A, Larson R, Nathan P. Fusion of the dominant negative transcription regulator CHOP with a novel gene FUS by translocation t(12;16) in malignant liposarcoma. Nat Genet 1993;4:175-80.
17. Shortman K, Wu L. Early T lymphocyte progenitors. Annu Rev Immunol 1996;14:29-47.
18. Palmiter RD, Brinster RL. Germ-line transformation of mice. Annu Rev Genet 1986;20:465-99.
19. Lang G, Wotton D, Owen MJ, et al. The structure of the human CD2 gene and its expression in transgenic mice. EMBO J 1988;7:1675-82.
20. Kishihara K, Penninger J, Wallace VA, et al. Normal B lymphocyte development but impaired T cell maturation in CD45-exon6 protein tyrosine phosphatase-deficient mice. Cell 1993;74:143-56.
21. Suzuki A, Iida S, Kato-Uranishi M, et al. ARK5 is transcriptionally regulated by the Large-MAF family and mediates IGF-1-induced cell invasion in multiple myeloma: ARK5 as a new molecular determinant of malignant multiple myeloma. Oncogene 2005;24:6936-44.
22. Hardie DG, Carling D. The AMP-activated protein kinase-fuel gauge of the mammalian cell? Eur J Biochem 1997;246:259-73.
23. Kemp BE, Mitchelhill KI, Stapleton D, et al. Dealing with energy demand: the AMP-activated protein kinase. Trends Biochem Sci 1999;24:22-5.
24. Kemp BE, Stapleton D, Campbell DJ, et al. AMP-activated protein kinase, super metabolic regulator. Biochem Soc Trans 2003;31:162-8.
25. Suzuki A, Lu J, Kusakai G, Kishimoto A, Ogura T, Esumi, H. ARK5 is a tumor invasion-associated factor downstream of Akt signaling. Mol Cell Biol 2004;24:3526-35.
26. Kataoka K, Nishizawa M, Kawai S. Structure-function analysis of the maf oncogene product, a member of the b-Zip protein family. J Virol 1993;67:2133-41.
27. Larson RC, Fisch P, Larson TA, et al. T cell tumours of disparate phenotype in mice transgenic for Rbtn-2. Oncogene 1994;9:3675-81.
28. Clark SS, Chen E, Fizzotti M, Witte ON, Malkovska V. BCR-ABL and v-abl oncogenes induce distinct patterns of thymic lymphoma involving different lymphocyte subsets. J Virol 1993;67:6033-46.
29. Xu Y, Sumter TF, Bhattacharya R, et al. The HMG-I oncogene causes highly penetrant, aggressive lymphoid malignancy in transgenic mice and is overexpressed in human leukemia. Cancer Res 2004;64:3371-5.
30. Jimenez M, Perez de Castro I, Benet M, Garcia JF, Inghirami G, Pellicer A. The Rgr oncogene induces tumorigenesis in transgenic mice. Cancer Res 2004;64:6041-9.
31. Anderson KC. Multiple Myeloma. Advances in disease biology: therapeutic implications. Semin Hematol 2001;38:6-10.
32. Shain KH, Landowski TH, Buyuksal I, Cantor AB, Dalton WS. Clonal variability in CD95 expression is the major determinant in Fas-medicated, but not chemotherapy-medicated apoptosis in the RPMI 8226 multiple myeloma cell line. Leukemia 2000;14:830-40.
33. Kusakai G, Suzuki A, Ogura T, et al. ARK5 expression in colorectal cancer and its implications for tumor progression. Am J Pathol 2004;164:987-95.
34. Zhao WL, Mourah S, Mounier N, et al. Vascular endothelial growth factor-A is expressed both on lymphoma cells and endothelial cells in angioimmunoblastic T-cell lymphoma and related to lymphoma progression. Lab Invest 2004;84:1512-9.